Travere Therapeutics is testing a buy point of 21.35, according to IBD MarketSurge. Shares are taking a pause after a smooth ...

Shares of Travere Therapeutics were trading at $20.08 as of April 29. Over the last 52-week period, shares are up 236.04%.

Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropathy (IgAN). Net sales of FILSPARI increased 13% ...

Welcome to the Travere Therapeutics' first-quarter 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Victoria ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share. The drug developer posted revenue of $81.7 ...

As you might know, Travere Therapeutics, Inc. ( NASDAQ:TVTX ) just kicked off its latest quarterly results with ...

ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...

Good afternoon, and welcome to the Travere Therapeutics First Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the ...

Travere Therapeutics demonstrated strong performance in Q1 2025 with significant growth in FILSPARI sales and progress on regulatory fronts. The potential approval of FILSPARI for FSGS by ...